{"prompt": "['3 mg/kg/week group who was previously treated with FVIII prophylaxis and had a baseline ABR of 0', '(in this patient, the ABR was maintained at 0 while receiving emicizumab). Among all patients,', 'percentage reduction in ABR ranged from 22.8% to 100% in the 0.3 mg/kg/week group, from 57.5%', 'to 100% in the 1 mg/kg/week group, and from 90.1% to 100% in the 3 mg/kg/week group.', 'The safety data from completed studies of healthy male volunteers (Japanese and Caucasian) in', 'ACE001JP Parts A and B (n=48) showed that emicizumab was well tolerated and the incidence of', 'adverse events was similar in the emicizumab dosing groups and the placebo group. Moreover, no', 'racial differences or dose-dependent increases in the incidence of adverse events were observed. There', 'were no serious adverse events, adverse events leading to discontinuation, or deaths in either study.', 'From ACE001JP Part C and its ongoing extension ACE002JP (as of the cut-off date 15 February', '2016), most adverse events were of mild or moderate intensity, except for 2 severe adverse events', '(appendicitis and mesenteric hematoma). The majority of the adverse events were not considered', \"related to emicizumab (see the Emicizumab Investigator's Brochure).\", '1.2.2.2', 'JP29574', 'Completed Study JP29574 included 5 groups of 12 healthy Japanese volunteers. This study', 'investigated the relative bioavailability between Phase I/II 80 mg/mL formulation and Phase III 150', 'mg/mL formulation materials and among three different sites of injection, as well as the absolute', 'bioavailability. Results showed no significant difference in the incidence of adverse events observed by', 'formulation, injection site, or administration route.', '1.2.2.3', 'Studies BH29884 and BH29992', 'The HAVEN 1 study (BH29884; NCT02622321) was a randomized, multicenter, open-label, clinical', 'trial in 109 adult and adolescent males (aged 12 to 75 years and > 40 kg) with hemophilia A with', 'FVIII inhibitors who previously received either episodic (on-demand) or prophylactic treatment with', 'bypassing agents. Patients received weekly emicizumab prophylaxis (Arms A, C, and D), 3 mg/kg', 'once weekly for the first 4 weeks followed by 1.5 mg/kg once weekly thereafter, or no prophylaxis', '(Arm B). Dose up-titration to 3 mg/kg once weekly was allowed after 24 weeks on emicizumab', 'prophylaxis in case of suboptimal efficacy (i.e., 2 spontaneous and clinically significant bleeds).', 'During the study, two patients underwent up-titration of their maintenance dose to 3 mg/kg once', 'weekly.', 'Fifty-three patients previously treated with episodic (on-demand) bypassing agents were randomized', 'in a 2:1 ratio to receive emicizumab prophylaxis (Arm A) or no prophylaxis (Arm B), with', 'stratification by prior 24-week bleed rate (< 9 or 9). Patients randomized to Arm B could switch to', 'emicizumab prophylaxis after completing at least 24 weeks without prophylaxis.', 'Forty-nine patients previously treated with prophylactic bypassing agents were enrolled into Arm C', 'to receive emicizumab prophylaxis. Seven patients previously treated with episodic (on-demand)', 'bypassing agents who had participated in a non-interventional study (NIS) prior to enrollment, but', 'were unable to enroll into HAVEN 1 prior to the closure of Arms A and B, were enrolled into Arm', 'D', 'to receive emicizumab prophylaxis.', 'Efficacy was evaluated based on the ABR requiring treatment with coagulation factors (minimum of', '24', 'weeks or date of discontinuation) among patients previously treated with episodic bypassing', 'Emicizumab - F. Hoffmann-La Roche Ltd', '93 / Protocol MO39129, Version 3']['agents who were randomized to emicizumab prophylaxis (Arm A) compared with those receiving no', 'prophylaxis (Arm B). The trial also evaluated the randomized comparison of Arms A and B for the', 'efficacy of weekly emicizumab prophylaxis in reducing the number of all bleeds, spontaneous bleeds,', 'joint bleeds, and target joint bleeds, as well as patient-reported symptoms and physical functioning.', 'The study also evaluated the efficacy of weekly emicizumab prophylaxis compared with previous', 'episodic (on-demand) and prophylactic bypassing agents in patients who had participated in the NIS', 'prior to enrollment (Arms A and C, respectively). Only patients from the NIS were included in this', 'comparison, because bleed and treatment data were collected with the same level of granularity in both', 'periods.', 'The efficacy results of emicizumab prophylaxis compared with no prophylaxis in bleed rate for treated', 'bleeds, all bleeds, treated spontaneous bleeds, treated joint bleeds and treated target joint bleeds are', 'shown in Table 1.', 'Table 2', 'Annualized Bleed Rate with Emicizumab Prophylaxis Arm versus No Prophylaxis', 'Arm in Patients 12 Years of Age', 'Emicizumab Prophylaxis', 'No Prophylaxis', 'Endpoint', '(N = 35)', '(N = 18)', 'Treated Bleeds', 'ABR (95% CI) [a]', '2.9 (1.7, 5.0)', '23.3 (12.3, 43.9)', '% reduction (95% CI)', '87% (72.3%, 94.3%)', 'p-value', '< 0.0001', '% patients with 0 bleeds (95% CI)', '62.9 (44.9, 78.5)', '5.6 (0.1, 27.3)', 'Median ABR (IQR)', '0 (0, 3.7)', '18.8 (13.0, 35.1)', 'All Bleeds', 'ABR (95% CI) [a]', '5.5 (3.6, 8.6)', '28.3 (16.8, 47.8)', '% reduction (95% CI)', '80% (62.5%, 89.8%)', 'p-value', '< 0.0001', '% patients with 0 bleeds (95% CI)', '37.1 (21.5, 55.1)', '5.6 (0.1, 27.3)', 'Treated Spontaneous Bleeds', 'ABR (95% CI) [a]', '1.3 (0.7,2.2)', '16.8 (9.9, 28.3)', '% reduction (95% CI)', '92% (84.6%, 96.3%)', 'p-value', '< 0.0001', '% patients with 0 bleeds (95% CI)', '68.6 (50.7, 83.1)', '11.1 (1.4, 34.7)', 'Treated Joint Bleeds', 'ABR (95% CI) [a]', '0.8 (0.3, 2.2)', '6.7 (2.0, 22.4)', '% reduction (95% CI)', '89% (48%, 97.5%)', 'p-value', '0.0050', '% patients with 0 bleeds (95% CI)', '85.7 (69.7, 95.2)', '50.0 (26.0, 74.0)', 'Treated Target Joint Bleeds', 'ABR (95% CI) [a]', '0.1 (0.03, 0.6)', '3.0 (1.0, 9.1)', 'Emicizumab - F. Hoffmann-La Roche Ltd', '94 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}